Case Control Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jun 7, 2017; 23(21): 3864-3875
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3864
Figure 1
Figure 1 Differential serum miRNA expression levels in non-infected healthy controls compared to hepatocellular carcinoma patients.
Figure 2
Figure 2 Efficacy of studied miRNAs in hepatocellular carcinoma non-malignant differentiation using receiver operating characteristics curve analysis. Hepatocellular carcinoma (HCC) (n = 224) and healthy control (n = 84).
Figure 3
Figure 3 Efficacy of studied miRNAs in hepatocellular carcinoma, hepatitis C virus categorization using receiver operating characteristics curve analysis. Hepatocellular carcinoma (n = 224) and hepatitis C virus (n = 250). AUC: Area under the curve.
Figure 4
Figure 4 Diagnostic activity of the panel of miRNAs studied.
Figure 5
Figure 5 Comparison between miRNA panel and alpha-fetoprotein using receiver operating characteristic curve. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.